Skip to main
HOLX

Hologic (HOLX) Stock Forecast & Price Target

Hologic (HOLX) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 18%
Hold 64%
Sell 0%
Strong Sell 0%

Bulls say

Hologic's diverse business segments, which include diagnostics, breast health, surgical, and skeletal health, are anticipated to contribute to organic revenue growth of 5-7% driven by strong procedure volumes and new product launches. Potential upside drivers such as improved revenue growth, higher operating margins, and strategic acquisitions could accelerate revenue growth to the high single digits (7-9%) while expanding operating margins and supporting 8-12% earnings growth. Additionally, Hologic's robust balance sheet and limited leverage enhance its financial stability and improve visibility on underlying business trends, positioning the company favorably for future growth.

Bears say

Hologic faces a negative outlook due to anticipated revenue growth slowing to low-single digits (1-4%), driven primarily by weakening performance in its Diagnostics and Breast Health segments. The company's historical stock performance has been lackluster, with only marginal returns over the past 3 and 5 years, coupled with sluggish demand in Breast Health exacerbated by a challenging global economic environment. Additionally, potential risks such as reduced hospital capital spending, market share loss, and obstacles from recent acquisitions further contribute to a pessimistic financial forecast for Hologic.

Hologic (HOLX) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 18% recommend Buy, 64% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hologic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hologic (HOLX) Forecast

Analysts have given Hologic (HOLX) a Hold based on their latest research and market trends.

According to 11 analysts, Hologic (HOLX) has a Hold consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hologic (HOLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.